Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2025)

Nuvalent (NUVL) posted Other Non-Current Liabilities of $35000.0 for Q4 2025, down 75.0% on a QoQ basis from $140000.0 in Q3 2025.

Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends

Nuvalent's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $35000.0 for Q4 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $35000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35000.0 (changed N/A YoY) and the FY2025 annual result came in at $35000.0, changed N/A from the prior year.
Other Non-Current Liabilities was $35000.0 for Q4 2025 at Nuvalent, down from $140000.0 in the prior quarter.
Across five years, Other Non-Current Liabilities topped out at $16.6 million in Q3 2024 and bottomed at $35000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Nuvalent	9.75 Bn	9.75 Bn	-

Download Data